| Assessment Status | Rapid Review Complete |
| HTA ID | 26032 |
| Drug | Mavorixafor |
| Brand | Xolremdi® |
| Indication | Mavorixafor (Xolremdi®) is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. |
| Assessment Process | |
| Rapid review commissioned | 03/07/2026 |
| Rapid review completed | 30/07/2026 |
| Rapid review outcome | A full HTA is not recommended. On the basis of current evidence, the NCPE recommends that mavorixafor not be considered for reimbursement*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here